<p>Viking Therapeutics, Inc.（纳斯达克代码：VKTX - 获取免费报告）在一月份经历了显著的空头头寸增长。截至 1 月 31 日，空头头寸总计为 23,930,000 股，比 1 月 15 日的 20,200,000 股增长了 18.5%。根据平均交易量 4,060,000 股，目前的空头头寸比率为 5.9 天。</p>
<p>获取 <strong>Viking Therapeutics</strong> 的提醒：</p>
<h2>内部人士下注</h2>
<ul>
<li>MarketBeat 周报 – 10/28 - 11/1</li>
</ul>
<p>在其他新闻中，首席运营官 Marianna Mancini 在 1 月 6 日星期一出售了 54,215 股 Viking Therapeutics 的股票。该股票以平均价格 42.75 美元出售，总交易额为 2,317,691.25 美元。出售后，首席运营官现在持有 374,134 股公司股票，价值约为 15,994,228.50 美元。此次交易使其持股减少了 12.66%。该交易已在向 SEC 提交的文件中披露，相关信息可通过 SEC 网站访问。此外，首席财务官 Greg Zante 在 1 月 6 日星期一出售了 50,309 股 Viking Therapeutics 的股票。该股票以平均价格 42.75 美元出售，总价值为 2,150,709.75 美元。出售后，首席财务官现在直接持有 165,259 股公司股票，价值约为 7,064,822.25 美元。这笔交易代表其持股减少了 23.34%。该出售的披露信息可在此处找到。内部人士在过去一个季度出售了 299,014 股公司股票，价值为 12,782,849 美元。内部人士持有公司 4.70% 的股份。</p>
<h2>对 Viking Therapeutics 的对冲基金看法</h2>
<p>对冲基金和其他机构投资者最近增加或减少了对公司的持股。Blue Trust Inc.在第三季度获得了 Viking Therapeutics 的新头寸，价值约为 26,000 美元。GAMMA Investing LLC 在第三季度将其在 Viking Therapeutics 的股份增加了 124.6%。GAMMA Investing LLC 现在拥有 438 股该生物技术公司的股票，价值 28,000 美元，此前在该期间又购买了 243 股。Stone House Investment Management LLC 在第三季度将其在 Viking Therapeutics 的股份增加了 66.7%。Stone House Investment Management LLC 现在拥有 500 股该生物技术公司的股票，价值 32,000 美元，此前在该期间又购买了 200 股。Gilliland Jeter Wealth Management LLC 在第三季度获得了 Viking Therapeutics 的新股份，价值 32,000 美元。最后，CNB Bank 在第三季度获得了 Viking Therapeutics 的新股份，价值 49,000 美元。机构投资者和对冲基金持有公司 76.03% 的股份。</p>
<h2>分析师评级升级与降级</h2>
<ul>
<li>Viking Therapeutics 股票：值得考虑的选举前投资</li>
</ul>
<p>VKTX 最近成为多份分析师报告的主题。花旗集团在 2 月 7 日星期五对 Viking Therapeutics 启动了覆盖。他们对该股票设定了 “中性” 评级和 38.00 美元的目标价。B. Riley 在 2 月 7 日星期五的研究报告中重申了 “买入” 评级，并将 Viking Therapeutics 的目标价设定为 96.00 美元（之前为 109.00 美元）。William Blair 在 11 月 20 日星期三的研究报告中重申了对 Viking Therapeutics 的 “跑赢大盘” 评级。Raymond James 在 2 月 6 日星期四的研究报告中将 Viking Therapeutics 的目标价从 122.00 美元上调至 125.00 美元，并给予公司 “强力买入” 评级。最后，Scotiabank 在周四的研究报告中开始覆盖 Viking Therapeutics 的股票。他们对该股票设定了 “行业跑赢大盘” 评级和 102.00 美元的目标价。一位股票研究分析师对该股票给予了卖出评级，一位给予了持有评级，十三位给予了买入评级，一位给予了强力买入评级。根据 MarketBeat 的数据，该股票目前的平均评级为 “适度买入”，共识目标价为 97.29 美元。</p>
<p><strong>获取我们对 Viking Therapeutics 的最新股票分析</strong></p>
<h2>Viking Therapeutics 价格表现</h2>
<ul>
<li>Viking Therapeutics 准备再次上涨吗？</li>
</ul>
<p>Viking Therapeutics 的股票在周五的午盘交易中上涨了 0.98 美元，达到 30.48 美元。该股票的交易量为 3,279,795 股，而其平均交易量为 4,270,754 股。该公司的 50 日简单移动平均线为 37.97 美元，200 日简单移动平均线为 52.88 美元。Viking Therapeutics 的 12 个月低点为 28.64 美元，12 个月高点为 99.41 美元。该公司的市值为 34 亿美元，市盈率为-30.48，贝塔值为 0.90。</p>
<p>Viking Therapeutics（纳斯达克代码：VKTX - 获取免费报告）最近在 2 月 5 日星期三发布了季度收益数据。这家生物技术公司报告本季度每股收益（EPS）为-0.32 美元，低于分析师的共识预期（-0.27 美元）0.05 美元。在去年同期，该公司每股收益为-0.25 美元。整体来看，卖方分析师预测 Viking Therapeutics 在当前财年将发布-1.41 美元的每股收益。</p>
<h2>关于 Viking Therapeutics</h2>
<p>（获取免费报告）</p>
<p>Viking Therapeutics, Inc.是一家临床阶段的生物制药公司，专注于开发用于代谢和内分泌疾病的新疗法。该公司的主要药物候选者是 VK2809，一种口服可用的选择性甲状腺激素受体β（TRß）激动剂，目前正在进行 IIb 期临床试验，以治疗经活检确认的非酒精性脂肪性肝炎以及非酒精性脂肪肝病（NAFLD）。</p>
<h2>精选故事</h2>
<ul>
<li>我们更喜欢的五只股票胜过 Viking Therapeutics</li>
<li>什么是股息之王？</li>
<li>Roblox 的大幅下跌：进入这只备受推崇的游戏股票的机会？</li>
<li>什么是 FTSE 100 指数？</li>
<li>3 只股息 ETF 以利用芯片股票的下滑</li>
<li>零售股票投资，解释</li>
<li>雪佛龙股票在利润提升消息后是否准备增长？</li>
</ul>
<p><em>此即时新闻提醒是由叙事科学技术和来自 MarketBeat 的金融数据生成的，旨在为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该把$1,000 投资在哪里？</h2>
<p>在你进行下一笔交易之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。</p>
<p>我们的团队已确定五只股票，顶级分析师正在悄悄地向他们的客户推荐在市场广泛关注之前购买……而且这些大牌股票都不在名单上。</p>
<p>他们认为这五只股票是投资者现在应该购买的五家最佳公司……</p>
<p>在这里查看这五只股票</p>
<h2>你现在应该把$1,000 投资于 Viking Therapeutics 吗？</h2>
<p>在你考虑 Viking Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已确定五只股票，顶级分析师正在悄悄地向他们的客户推荐在市场广泛关注之前购买……而 Viking Therapeutics 不在名单上。</p>
<p>虽然 Viking Therapeutics 目前在分析师中有 “买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

Viking治疗

<p>Viking Therapeutics, Inc.（纳斯达克代码：VKTX）在 1 月份的空头头寸增加了 18.5%，截至 1 月 31 日，总计达到 23,930,000 股。根据平均交易量 4,060,000 股，覆盖天数比率为 5.9 天。此外，内部人士在上个季度出售了价值 1278 万美元的 299,014 股。机构投资者持有该公司 76.03% 的股份，各种分析师对其评级和目标价格意见不一，目标价格范围从 38.00 美元到 125.00 美元。目前该股交易价格为 30.48 美元，过去十二个月的价格区间为 28.64 美元至 99.41 美元</p>

<p>Viking Therapeutics, Inc. (NASDAQ:VKTX - Get Free Report) was the recipient of a significant growth in short interest during the month of January. As of January 31st, there was short interest totalling 23,930,000 shares, a growth of 18.5% from the January 15th total of 20,200,000 shares. Based on an average trading volume of 4,060,000 shares, the short-interest ratio is currently 5.9 days.</p>
<div class="lb-trans"><p>Viking Therapeutics, Inc.（纳斯达克代码：VKTX - 获取免费报告）在一月份经历了显著的空头头寸增长。截至 1 月 31 日，空头头寸总计为 23,930,000 股，比 1 月 15 日的 20,200,000 股增长了 18.5%。根据平均交易量 4,060,000 股，目前的空头头寸比率为 5.9 天。</p>
</div><p>Get <strong>Viking Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Viking Therapeutics</strong> 的提醒：</p>
</div><h2>Insiders Place Their Bets</h2>
<div class="lb-trans"><h2>内部人士下注</h2>
</div><ul>
<li>MarketBeat Week in Review – 10/28 - 11/1</li>
</ul>
<div class="lb-trans"><ul>
<li>MarketBeat 周报 – 10/28 - 11/1</li>
</ul>
</div><p>In other news, COO Marianna Mancini sold 54,215 shares of Viking Therapeutics stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $42.75, for a total transaction of $2,317,691.25. Following the sale, the chief operating officer now owns 374,134 shares of the company's stock, valued at approximately $15,994,228.50. The trade was a 12.66 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO Greg Zante sold 50,309 shares of Viking Therapeutics stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $42.75, for a total value of $2,150,709.75. Following the sale, the chief financial officer now directly owns 165,259 shares in the company, valued at approximately $7,064,822.25. This trade represents a 23.34 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 299,014 shares of company stock valued at $12,782,849 over the last quarter. Insiders own 4.70% of the company's stock.</p>
<div class="lb-trans"><p>在其他新闻中，首席运营官 Marianna Mancini 在 1 月 6 日星期一出售了 54,215 股 Viking Therapeutics 的股票。该股票以平均价格 42.75 美元出售，总交易额为 2,317,691.25 美元。出售后，首席运营官现在持有 374,134 股公司股票，价值约为 15,994,228.50 美元。此次交易使其持股减少了 12.66%。该交易已在向 SEC 提交的文件中披露，相关信息可通过 SEC 网站访问。此外，首席财务官 Greg Zante 在 1 月 6 日星期一出售了 50,309 股 Viking Therapeutics 的股票。该股票以平均价格 42.75 美元出售，总价值为 2,150,709.75 美元。出售后，首席财务官现在直接持有 165,259 股公司股票，价值约为 7,064,822.25 美元。这笔交易代表其持股减少了 23.34%。该出售的披露信息可在此处找到。内部人士在过去一个季度出售了 299,014 股公司股票，价值为 12,782,849 美元。内部人士持有公司 4.70% 的股份。</p>
</div><h2>Hedge Funds Weigh In On Viking Therapeutics</h2>
<div class="lb-trans"><h2>对 Viking Therapeutics 的对冲基金看法</h2>
</div><p>Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Blue Trust Inc. acquired a new position in Viking Therapeutics in the 3rd quarter worth approximately $26,000. GAMMA Investing LLC boosted its stake in shares of Viking Therapeutics by 124.6% during the 3rd quarter. GAMMA Investing LLC now owns 438 shares of the biotechnology company's stock valued at $28,000 after buying an additional 243 shares during the period. Stone House Investment Management LLC boosted its stake in shares of Viking Therapeutics by 66.7% during the 3rd quarter. Stone House Investment Management LLC now owns 500 shares of the biotechnology company's stock valued at $32,000 after buying an additional 200 shares during the period. Gilliland Jeter Wealth Management LLC acquired a new stake in shares of Viking Therapeutics during the 3rd quarter valued at $32,000. Finally, CNB Bank acquired a new stake in shares of Viking Therapeutics during the 3rd quarter valued at $49,000. Institutional investors and hedge funds own 76.03% of the company's stock.</p>
<div class="lb-trans"><p>对冲基金和其他机构投资者最近增加或减少了对公司的持股。Blue Trust Inc.在第三季度获得了 Viking Therapeutics 的新头寸，价值约为 26,000 美元。GAMMA Investing LLC 在第三季度将其在 Viking Therapeutics 的股份增加了 124.6%。GAMMA Investing LLC 现在拥有 438 股该生物技术公司的股票，价值 28,000 美元，此前在该期间又购买了 243 股。Stone House Investment Management LLC 在第三季度将其在 Viking Therapeutics 的股份增加了 66.7%。Stone House Investment Management LLC 现在拥有 500 股该生物技术公司的股票，价值 32,000 美元，此前在该期间又购买了 200 股。Gilliland Jeter Wealth Management LLC 在第三季度获得了 Viking Therapeutics 的新股份，价值 32,000 美元。最后，CNB Bank 在第三季度获得了 Viking Therapeutics 的新股份，价值 49,000 美元。机构投资者和对冲基金持有公司 76.03% 的股份。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析师评级升级与降级</h2>
</div><ul>
<li>Viking Therapeutics Stock: A Pre-Election Bet Worth Considering</li>
</ul>
<div class="lb-trans"><ul>
<li>Viking Therapeutics 股票：值得考虑的选举前投资</li>
</ul>
</div><p>VKTX has been the topic of a number of recent analyst reports. Citigroup initiated coverage on Viking Therapeutics in a report on Friday, February 7th. They set a &#34;neutral&#34; rating and a $38.00 price target on the stock. B. Riley reiterated a &#34;buy&#34; rating and set a $96.00 price objective (down previously from $109.00) on shares of Viking Therapeutics in a research note on Friday, February 7th. William Blair reiterated an &#34;outperform&#34; rating on shares of Viking Therapeutics in a research note on Wednesday, November 20th. Raymond James raised their price objective on shares of Viking Therapeutics from $122.00 to $125.00 and gave the company a &#34;strong-buy&#34; rating in a research note on Thursday, February 6th. Finally, Scotiabank began coverage on shares of Viking Therapeutics in a research note on Thursday. They set a &#34;sector outperform&#34; rating and a $102.00 price objective on the stock. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of &#34;Moderate Buy&#34; and a consensus price target of $97.29.</p>
<div class="lb-trans"><p>VKTX 最近成为多份分析师报告的主题。花旗集团在 2 月 7 日星期五对 Viking Therapeutics 启动了覆盖。他们对该股票设定了 “中性” 评级和 38.00 美元的目标价。B. Riley 在 2 月 7 日星期五的研究报告中重申了 “买入” 评级，并将 Viking Therapeutics 的目标价设定为 96.00 美元（之前为 109.00 美元）。William Blair 在 11 月 20 日星期三的研究报告中重申了对 Viking Therapeutics 的 “跑赢大盘” 评级。Raymond James 在 2 月 6 日星期四的研究报告中将 Viking Therapeutics 的目标价从 122.00 美元上调至 125.00 美元，并给予公司 “强力买入” 评级。最后，Scotiabank 在周四的研究报告中开始覆盖 Viking Therapeutics 的股票。他们对该股票设定了 “行业跑赢大盘” 评级和 102.00 美元的目标价。一位股票研究分析师对该股票给予了卖出评级，一位给予了持有评级，十三位给予了买入评级，一位给予了强力买入评级。根据 MarketBeat 的数据，该股票目前的平均评级为 “适度买入”，共识目标价为 97.29 美元。</p>
</div><p><strong>Get Our Latest Stock Analysis on Viking Therapeutics</strong></p>
<div class="lb-trans"><p><strong>获取我们对 Viking Therapeutics 的最新股票分析</strong></p>
</div><h2>Viking Therapeutics Price Performance</h2>
<div class="lb-trans"><h2>Viking Therapeutics 价格表现</h2>
</div><ul>
<li>Is Viking Therapeutics Ready For Another Surge?</li>
</ul>
<div class="lb-trans"><ul>
<li>Viking Therapeutics 准备再次上涨吗？</li>
</ul>
</div><p>Viking Therapeutics stock traded up $0.98 during midday trading on Friday, reaching $30.48. The stock had a trading volume of 3,279,795 shares, compared to its average volume of 4,270,754. The firm's fifty day simple moving average is $37.97 and its two-hundred day simple moving average is $52.88. Viking Therapeutics has a twelve month low of $28.64 and a twelve month high of $99.41. The firm has a market cap of $3.40 billion, a price-to-earnings ratio of -30.48 and a beta of 0.90.</p>
<div class="lb-trans"><p>Viking Therapeutics 的股票在周五的午盘交易中上涨了 0.98 美元，达到 30.48 美元。该股票的交易量为 3,279,795 股，而其平均交易量为 4,270,754 股。该公司的 50 日简单移动平均线为 37.97 美元，200 日简单移动平均线为 52.88 美元。Viking Therapeutics 的 12 个月低点为 28.64 美元，12 个月高点为 99.41 美元。该公司的市值为 34 亿美元，市盈率为-30.48，贝塔值为 0.90。</p>
</div><p>Viking Therapeutics (NASDAQ:VKTX - Get Free Report) last posted its quarterly earnings data on Wednesday, February 5th. The biotechnology company reported ($0.32) EPS for the quarter, missing analysts' consensus estimates of ($0.27) by ($0.05). During the same period in the previous year, the business earned ($0.25) EPS. As a group, sell-side analysts predict that Viking Therapeutics will post -1.41 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Viking Therapeutics（纳斯达克代码：VKTX - 获取免费报告）最近在 2 月 5 日星期三发布了季度收益数据。这家生物技术公司报告本季度每股收益（EPS）为-0.32 美元，低于分析师的共识预期（-0.27 美元）0.05 美元。在去年同期，该公司每股收益为-0.25 美元。整体来看，卖方分析师预测 Viking Therapeutics 在当前财年将发布-1.41 美元的每股收益。</p>
</div><h2>About Viking Therapeutics</h2>
<div class="lb-trans"><h2>关于 Viking Therapeutics</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.</p>
<div class="lb-trans"><p>Viking Therapeutics, Inc.是一家临床阶段的生物制药公司，专注于开发用于代谢和内分泌疾病的新疗法。该公司的主要药物候选者是 VK2809，一种口服可用的选择性甲状腺激素受体β（TRß）激动剂，目前正在进行 IIb 期临床试验，以治疗经活检确认的非酒精性脂肪性肝炎以及非酒精性脂肪肝病（NAFLD）。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than Viking Therapeutics</li>
<li>What is a Dividend King?</li>
<li>Roblox's Big Dip: A Chance to Get in on the Vaunted Gaming Stock?</li>
<li>What is the FTSE 100 index?</li>
<li>3 Dividend ETFs to Capitalize on the Slide in Chip Stocks</li>
<li>Retail Stocks Investing, Explained</li>
<li>Is Chevron Stock Primed for Growth After Profit-Boosting News?</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更喜欢的五只股票胜过 Viking Therapeutics</li>
<li>什么是股息之王？</li>
<li>Roblox 的大幅下跌：进入这只备受推崇的游戏股票的机会？</li>
<li>什么是 FTSE 100 指数？</li>
<li>3 只股息 ETF 以利用芯片股票的下滑</li>
<li>零售股票投资，解释</li>
<li>雪佛龙股票在利润提升消息后是否准备增长？</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒是由叙事科学技术和来自 MarketBeat 的金融数据生成的，旨在为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><h2>Where Should You Invest $1,000 Right Now?</h2>
<div class="lb-trans"><h2>你现在应该把$1,000 投资在哪里？</h2>
</div><p>Before you make your next trade, you'll want to hear this.</p>
<div class="lb-trans"><p>在你进行下一笔交易之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。</p>
</div><p>Our team has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and none of the big name stocks were on the list.</p>
<div class="lb-trans"><p>我们的团队已确定五只股票，顶级分析师正在悄悄地向他们的客户推荐在市场广泛关注之前购买……而且这些大牌股票都不在名单上。</p>
</div><p>They believe these five stocks are the five best companies for investors to buy now...</p>
<div class="lb-trans"><p>他们认为这五只股票是投资者现在应该购买的五家最佳公司……</p>
</div><p>See The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div><h2>Should You Invest $1,000 in Viking Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该把$1,000 投资于 Viking Therapeutics 吗？</h2>
</div><p>Before you consider Viking Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Viking Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Viking Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已确定五只股票，顶级分析师正在悄悄地向他们的客户推荐在市场广泛关注之前购买……而 Viking Therapeutics 不在名单上。</p>
</div><p>While Viking Therapeutics currently has a &#34;Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Viking Therapeutics 目前在分析师中有 “买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Viking Therapeutics, Inc.（纳斯达克股票代码：VKTX）1 月份的空头头寸增加了 18.5%